Switch theme
Sign up to access all valuation multiples
Imricor Medical Systems Inc is a medical device company that develops MRI-guided technology to address issues with traditional X-ray ablation procedures. Its principal business activities are designing, manufacturing, and selling MRI-compatible products for cardiac catheter ablation procedures to treat arrhythmias. The company's products include the Advantage-MR EP Recorder/Stimulator, Vision-MR Ablation Catheter, and Vision-MR Dispersive Electrode. Geographically, the company generates maximum revenue from Europe, followed by the Middle East and the United States.
2006
n/a
LTM Revenue $3.5M
LTM EBITDA -$23.9M
$364M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Imricor Medical Systems has a last 12-month revenue (LTM) of $3.5M and a last 12-month EBITDA of -$23.9M.
In the most recent fiscal year, Imricor Medical Systems achieved revenue of $0.6M and an EBITDA of -$18.6M.
Imricor Medical Systems expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Imricor Medical Systems valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $3.5M | XXX | $0.6M | XXX | XXX | XXX |
| Gross Profit | $3.5M | XXX | -$0.6M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | -96% | XXX | XXX | XXX |
| EBITDA | -$23.9M | XXX | -$18.6M | XXX | XXX | XXX |
| EBITDA Margin | -677% | XXX | -3015% | XXX | XXX | XXX |
| EBIT | -$24.6M | XXX | -$11.0M | XXX | XXX | XXX |
| EBIT Margin | -696% | XXX | -1779% | XXX | XXX | XXX |
| Net Profit | -$37.5M | XXX | -$19.1M | XXX | XXX | XXX |
| Net Margin | -1062% | XXX | -3095% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $2.9M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Imricor Medical Systems's stock price is AUD 2 (or $1).
Imricor Medical Systems has current market cap of AUD 558M (or $358M), and EV of AUD 566M (or $364M).
See Imricor Medical Systems trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $364M | $358M | XXX | XXX | XXX | XXX | $-0.10 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Imricor Medical Systems has market cap of $358M and EV of $364M.
Imricor Medical Systems's trades at 590.3x EV/Revenue multiple, and -19.6x EV/EBITDA.
Equity research analysts estimate Imricor Medical Systems's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Imricor Medical Systems has a P/E ratio of -14.9x.
See valuation multiples for Imricor Medical Systems and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $358M | XXX | $358M | XXX | XXX | XXX |
| EV (current) | $364M | XXX | $364M | XXX | XXX | XXX |
| EV/Revenue | 160.2x | XXX | 590.3x | XXX | XXX | XXX |
| EV/EBITDA | -23.7x | XXX | -19.6x | XXX | XXX | XXX |
| EV/EBIT | -23.0x | XXX | -33.2x | XXX | XXX | XXX |
| EV/Gross Profit | 160.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | -14.9x | XXX | -18.8x | XXX | XXX | XXX |
| EV/FCF | -24.5x | XXX | -36.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialImricor Medical Systems's last 12 month revenue growth is 331%
Imricor Medical Systems's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Imricor Medical Systems's rule of 40 is -3222% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Imricor Medical Systems's rule of X is 151% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Imricor Medical Systems and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 331% | XXX | 438% | XXX | XXX | XXX |
| EBITDA Margin | -677% | XXX | -3015% | XXX | XXX | XXX |
| EBITDA Growth | -28% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -3222% | XXX | -2684% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 151% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 237% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 853% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 1682% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Imricor Medical Systems acquired XXX companies to date.
Last acquisition by Imricor Medical Systems was XXXXXXXX, XXXXX XXXXX XXXXXX . Imricor Medical Systems acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Imricor Medical Systems founded? | Imricor Medical Systems was founded in 2006. |
| Where is Imricor Medical Systems headquartered? | Imricor Medical Systems is headquartered in Australia. |
| Is Imricor Medical Systems publicy listed? | Yes, Imricor Medical Systems is a public company listed on ASX. |
| What is the stock symbol of Imricor Medical Systems? | Imricor Medical Systems trades under IMR ticker. |
| When did Imricor Medical Systems go public? | Imricor Medical Systems went public in 2019. |
| Who are competitors of Imricor Medical Systems? | Similar companies to Imricor Medical Systems include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Imricor Medical Systems? | Imricor Medical Systems's current market cap is $358M |
| What is the current revenue of Imricor Medical Systems? | Imricor Medical Systems's last 12 months revenue is $3.5M. |
| What is the current revenue growth of Imricor Medical Systems? | Imricor Medical Systems revenue growth (NTM/LTM) is 331%. |
| What is the current EV/Revenue multiple of Imricor Medical Systems? | Current revenue multiple of Imricor Medical Systems is 160.2x. |
| Is Imricor Medical Systems profitable? | Yes, Imricor Medical Systems is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Imricor Medical Systems? | Imricor Medical Systems's last 12 months EBITDA is -$23.9M. |
| What is Imricor Medical Systems's EBITDA margin? | Imricor Medical Systems's last 12 months EBITDA margin is -677%. |
| What is the current EV/EBITDA multiple of Imricor Medical Systems? | Current EBITDA multiple of Imricor Medical Systems is -23.7x. |
| What is the current FCF of Imricor Medical Systems? | Imricor Medical Systems's last 12 months FCF is -$23.1M. |
| What is Imricor Medical Systems's FCF margin? | Imricor Medical Systems's last 12 months FCF margin is -654%. |
| What is the current EV/FCF multiple of Imricor Medical Systems? | Current FCF multiple of Imricor Medical Systems is -24.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
